Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KCNA5 | P22460 | 2/20 | 0.41 |
| ▸ | KCNN4 | O15554 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 2/20 | 0.40 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.36 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.35 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17333403 | 0.84 | ESR1 (0.60) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL15672925 | 0.81 | ESR1 (0.57) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL28805129 | 0.80 | HSP90AA1 (0.35) | ESR1KMT2ATSHRMAPK1HSD17B10 | |
| SCHEMBL17333633 | 0.80 | ESR1 (0.55) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL17333393 | 0.78 | ESR1 (0.54) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL17333701 | 0.78 | ESR1 (0.54) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL17333608 | 0.77 | HSP90AA1 (0.54) | ESR1KMT2AMEN1TP53TSHR | |
| SCHEMBL17333618 | 0.75 | ESR1 (0.58) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL17333563 | 0.75 | ESR1 (0.51) | ESR1KMT2AMEN1KCNA5TP53 | |
| SCHEMBL17333461 | 0.75 | ESR1 (0.51) | ESR1KMT2AMEN1KCNA5TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7217737-B2 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH AND DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) | 2007-05-15 | — | — | US | disclosed |
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM | 2004-12-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040242684-A1 | Method and compositions for inhibiting cell proliferative disorders | ERBB2, EGFR, MKI67 | ESR1 835/4885KMT2A 1810/4885MEN1 2723/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.